BodyPharm Retratrutide PEN 64mg

Retatrutide is a peptide currently under advanced clinical investigation for its activity across multiple metabolic pathways. It is designed to act on three key receptors involved in glucose and energy regulation:

• GLP-1 (glucagon-like peptide-1)

• GIP (glucose-dependent insulinotropic polypeptide)

• Glucagon receptors

Through this triple-agonist mechanism, retatrutide has been studied for its effects on insulin secretion, regulation of glucose production, gastric emptying, and appetite-related signalling.

Clinical Trial Status

As of 2025, retatrutide remains under investigation and is not yet formally approved for general medical use.

• Phase 2 clinical studies reported significant outcomes, with participants experiencing an average body-weight reduction of approximately 24.2% over 48 weeks under controlled trial conditions.

• Phase 3 clinical trials are ongoing and have reported continued, clinically meaningful effects consistent with earlier trial phases, further evaluating long-term safety, efficacy, and tolerability. Final data and regulatory review are pending.

No guarantees of outcome can be inferred outside of controlled clinical settings.

How Retatrutide Compares

Retatrutide is often discussed alongside other incretin-based compounds:

• Semaglutide acts primarily as a GLP-1 receptor agonist

• Tirzepatide is a dual agonist, targeting both GLP-1 and GIP receptors

• Retatrutide is a triple agonist, additionally engaging the glucagon receptor, which differentiates its investigational profile from earlier-generation compounds

Important Information

• Supplied as a pre-filled injectable pen
  

• Retatrutide remains an investigational compound

• Consultation with a licensed healthcare provider is essential prior to any consideration of use

• Results observed in clinical trials may not reflect real-world outcomes

This product is supplied strictly on an informed purchaser basis. By purchasing, you acknowledge that:

• You have independently researched this product and its investigational status

• You have consulted, or will consult, a qualified healthcare professional

• You understand that retatrutide is not yet approved and remains subject to ongoing clinical evaluation

• The seller provides no medical advice, treatment claims, or dosing guidance

• The onus of lawful, safe, and appropriate use rests entirely with the purchaser